Infection risk and cancer chemotherapy: The impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. D, 1998, Pages 1-5

  Bow, Eric J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; FEVER; HUMAN; INFECTION RISK; LYMPHOMA; NEUTROPENIA; SHORT SURVEY; SOLID TUMOR;

EID: 0031777272     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_4.1     Document Type: Short Survey

References (45)

1. Kontoyiannis, D. P. & Rubin, R. H. (1995). Infection in the organ transplant recipient. An overview. Infectious Disease Clinics of North America 9, 811-22.
2. Chabner, B. A. (1996). Anticancer drugs, In Cancer: Principles and Practice of Oncology, 4th edn (De Vita, V. T., Hellman, S. & Rosenberg, S. A., Eds), pp. 325-417. Lippincott, Philadelphia, PA.
3. Blay, J.-Y., Chauvin, F., Le Cesne, A., Anglaret, B., Bouhour, D., Lasset, C. et al. (1996). Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Journal of Clinical Oncology 14, 636-43.
4. Bodey, G. P., Buckley, M., Sathe, Y. S. & Freireich, E. J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64, 328-40.
5. Gordon, L. I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R. et al. (1992). Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine 327, 1342-9.
6. Meyer, R. M., Quirt, I. C., Skillings, J. R., Cripps, M. C., Bramwell, V. H. C., Weinerman, B. H. et al. (1993). Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New England Journal of Medicine 329, 1770-6.
7. Nichols, C. R., Fox, E. P., Roth, B. J., Williams, S. D., Loehrer, P. J. & Einhorn, L. H. (1994). Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. Journal of Clinical Oncology 12, 1245-50.
8. Shipp, M. A., Yeap, B. Y., Harrington, D. P., Klatt, M. M., Pinkus, G. S., Jochelson, M. S. et al. (1990). The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the m-BACOD regimen. Journal of Clinical Oncology 8, 84-93.
9. ASCO ad hoc Colony-Stimulating Factor Guideline Expert Panel. (1994). American Society of Clinical Oncology. Recommendations for the use of haematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 12, 2471-508.
10. Klimo, P. & Connors, J. M. (1985). MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals of Internal Medicine 102, 596-602.
11. Velasquez, W. S., Cabinillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S. et al. (1988). Effective salvage therapy for lymphoma with cisplatin in combination with ARA-C and dexamethazone (DHAP). Blood 71, 117-22.
12. Dana, B. W., Dahlberg, S., Miller, T. P., Hartsock, R. J., Balcerzak, S., Coltman, C. A. et al. (1990). m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. Journal of Clinical Oncology 8, 1155-62.
13. Weick, J. K., Dahlberg, S., Fisher, R. I., Dana, B., Miller, T. P., Balcerzak, S. P. et al. (1991). Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. Journal of Clinical Oncology 9, 748-53.
14. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R., Wilkinson, P. M. et al. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80, 1430-6.
15. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M. et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 328, 1002-6.
16. Wilson, W. H., Bryant, G., Bates, S., Fujo, A., Wittes, R. E., Steinberg, S. M. et al. (1993). EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology 11, 1573-82.
17. Velasquez, W. S., McLaughlin, P., Tucker, S., Hogemeister, F. B., Swan, F., Rodrigez, M. A. et al. (1994). ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology 12, 1169-76.
18. Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J. et al. (1992). Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. Journal of Clinical Oncology 10, 282-91.
19. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I. et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 325, 164-70.
20. Bow, E. J., Kilpatrick, M. G., Scott, B. A., Clinch, J. J. & Cheang, M. S. (1994). Acute myeloid leukemia in Manitoba. The consequences of standard '7+3' remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 74, 52-60.
21. Bow, E. J., Sutherland, J. A., Kilpatrick, M. G., Williams, G. J., Clinch, J. J., Shore, T. B. et al. (1996). Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. Journal of Clinical Oncology 14, 1345-52.
22. Biesma, B., de Vries, E. G. E., Willemse, P. H. B., Sluiter, W. J., Postmus, P. E., Limberg, P. C. et al. (1990). Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer 26, 932-6.
23. Maher, D. W., Lieschke, G. J., Green, M., Bishop, J., Stuart-Harris, R., Wolf, M. et al. (1994). Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine 121, 492-501.
24. Mayordomo, J. I., Rivera, F., Diaz-Puente, M. T., Lianes, P., Colomer, R., Lopez-Brea, M. et al. (1995). Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute 87, 803-8.
25. Vellenga, E., Uyl-de Groot, C. A., de Wit, R., Keizer, H. J., Lowenberg, B., ten Haaft, M. A. et al. (1996). Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology 14, 619-27.
26. Hughes, W. T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
27. Bow, E. J. (1992). Approach to infections in patients receiving cytotoxic chemotherapy for malignancy. In Principles of Critical Care (Hall, J. B., Schmidt, G. A. & Wood, L. D. H., Eds), pp. 1186-207. McGraw-Hill, New York.
28. EORTC International Antimicrobial Therapy Project Group. (1978). Three antibiotic regimens in the treatment of infection in febrile, granulocytopenic patients with cancer. Journal of Infectious Diseases 137, 14-29.
29. Pizzo, P. A., Robichaud, K. J., Wesley, R. & Commers, J. R. (1982). Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine 61, 153-66.
30. Visoli, C., Bruzzi, P., Castagnola, E., Boni, L., Calandra, T., Gaya, H. et al. (1994). Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. European Journal of Cancer 30A, 430-7.
31. Immunocompromised Host Society. (1990). The design, analysis, and reporting of clinical trials on empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases 161, 397-401.
32. Figueredo, A. T., Hryniuk, W. M., Strautmanis, I., Frank, G. & Rendell, S. (1985). Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. Journal of Clinical Oncology 3, 54-64.
33. de Jongh, C. A., Wade, J. C., Finley, R. S., Joshi, J. H., Aisner, J., Wiernik, P. H. et al. (1983). Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. Journal of Clinical Oncology 1, 302-7.
34. Feld, R. & Bodey, G. P. (1977). Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39, 1018-25.
35. Meyer, R. M., Browman, G. P., Samosh, M. L., Benger, A. M., Bryant-Lukosius, D., Wilson, W. E. C. et al. (1995). Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology13, 2386-93.
36. Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P., Grozea, P. N. et al. (1986). Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 4, 295-305.
37. Longo, D. L., DeVita, V. T., Duffey, P. L., Wesley, M. N., Ihde, D. C., Hubberd, S. M. et al. (1991). Superiority of Pro-MACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal of Clinical Oncology 9, 25-38.
38. Shaw, M. T., Spector, M. H. & Ladman, A. J. (1979). Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treatment Reviews 6, 141-51.
39. Slavin, R. E., Dias, M. A. & Saral, R. (1978). Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols, a clinical-pathologic study of 33 patients. Cancer 42, 1747-59.
40. Deitch, E. A. (1989). Simple intestinal obstruction causes bacterial translocation in man. Archives of Surgery 124, 699-701.
41. Donnelly, J. P., Muus, P., Schattenberg, A., De Witte, T., Horrevorts, A. & DePauw, B. E. (1992). A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplantation 9, 409-13.
42. Bochud, P.-Y., Calandra, T. & Francioli, P. (1994). Bacteremia due to viridans streptococci in neutropenic patients: a review. American Journal of Medicine 97, 256-64.
43. Bow, E. J., Loewen, R., Cheang, M. S. & Schacter, B. (1995). Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases 21, 361-9.
44. Kasper, K., Loewen R. & Bow, E. J. (1996). Neutropenic enterocolitis in acute leukemia patients in Manitoba. In Program and Abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1996. Abstract 38, p.42. IDSA.
45. Wade, D. S., Nava, H. R. & Douglass, H. O. (1992). Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69, 17-23.